Xilio Therapeutics Inc (NAS:XLO)
$ 1.31 -0.13 (-9.03%) Market Cap: 57.58 Mil Enterprise Value: -3.85 Mil PE Ratio: 0 PB Ratio: 1.72 GF Score: 34/100

Xilio Therapeutics Inc Spotlight Program Transcript

Aug 17, 2023 / 04:30PM GMT
Release Date Price: $2.69 (-3.41%)
Operator

Good afternoon, and welcome to the Xilio Therapeutics Virtual Program Spotlight. (Operator Instructions) As a reminder, this program is being recorded and a replay will be made available on the Xilio Therapeutics website following the conclusion of today's event.

At this time, I would now like to turn the call over to your host, Stacey Davis, Chief Business Officer at Xilio.

Stacey J. Davis
Xilio Therapeutics, Inc. - Chief Business Officer

Thank you. Good day, everyone. Welcome to the Xilio Therapeutics Virtual Spotlight event focused on XTX101, a novel Fc-enhanced tumor-activated anti-CTLA-4. Thank you for joining us today. This is Stacey Davis, I'm a Chief Business Officer, and I'll be moderating today's call.

Before we get started, I'd like to remind everyone that the statements we make on this conference call will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot